[go: up one dir, main page]

EP1436395A4 - Methodes d'identification et d'utilisation de modulateurs du recepteur gamma dependant des oestrogenes - Google Patents

Methodes d'identification et d'utilisation de modulateurs du recepteur gamma dependant des oestrogenes

Info

Publication number
EP1436395A4
EP1436395A4 EP02776223A EP02776223A EP1436395A4 EP 1436395 A4 EP1436395 A4 EP 1436395A4 EP 02776223 A EP02776223 A EP 02776223A EP 02776223 A EP02776223 A EP 02776223A EP 1436395 A4 EP1436395 A4 EP 1436395A4
Authority
EP
European Patent Office
Prior art keywords
modulators
identifying
methods
receptor gamma
related receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02776223A
Other languages
German (de)
English (en)
Other versions
EP1436395A2 (fr
Inventor
Steven G Blanchard
Aaron Bayne Miller
Lisa A Orband-Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1436395A2 publication Critical patent/EP1436395A2/fr
Publication of EP1436395A4 publication Critical patent/EP1436395A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/108Osteoporosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/362Menopause

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02776223A 2001-10-16 2002-10-16 Methodes d'identification et d'utilisation de modulateurs du recepteur gamma dependant des oestrogenes Withdrawn EP1436395A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32988801P 2001-10-16 2001-10-16
US329888P 2001-10-16
PCT/US2002/032917 WO2003034028A2 (fr) 2001-10-16 2002-10-16 Methodes d'identification et d'utilisation de modulateurs du recepteur gamma dependant des oestrogenes

Publications (2)

Publication Number Publication Date
EP1436395A2 EP1436395A2 (fr) 2004-07-14
EP1436395A4 true EP1436395A4 (fr) 2006-12-13

Family

ID=23287445

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02776223A Withdrawn EP1436395A4 (fr) 2001-10-16 2002-10-16 Methodes d'identification et d'utilisation de modulateurs du recepteur gamma dependant des oestrogenes

Country Status (4)

Country Link
EP (1) EP1436395A4 (fr)
JP (1) JP2005509628A (fr)
AU (1) AU2002342058A1 (fr)
WO (1) WO2003034028A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130503A2 (fr) * 2005-05-27 2006-12-07 Janssen Pharmaceutica N.V. Complexes de fragments de peptides errg et utilisation de ceux-ci dans un nouveau medicament
KR101631581B1 (ko) * 2010-06-11 2016-06-17 한국생명공학연구원 나노입자가 융합된 fret 센서 및 이를 이용한 파이토에스트로겐을 고감도로 검출하는 방법
KR101579008B1 (ko) * 2013-09-25 2015-12-22 경북대학교 산학협력단 ERR-γ 저해제를 포함하는, 망막병증의 예방 또는 치료용 약학적 조성물 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096301A (en) * 1986-10-10 2000-08-01 Industria Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
US6218128B1 (en) * 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COWARD P ET AL: "4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 15, 17 July 2001 (2001-07-17), pages 8880 - 8884, XP002971442, ISSN: 0027-8424 *
HEARD D J ET AL: "Human ERRgamma, a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult.", MOLECULAR ENDOCRINOLOGY (BALTIMORE, MD.) MAR 2000, vol. 14, no. 3, March 2000 (2000-03-01), pages 382 - 392, XP002404547, ISSN: 0888-8809 *
SHIAU A K ET AL: "ORPHAN NUCLEAR RECEPTORS: FROM NEW LIGAND DISCOVERY TECHNOLOGIES TO NOVEL SIGNALING PATHWAYS", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 4, no. 5, September 2001 (2001-09-01), pages 575 - 590, XP009031659, ISSN: 1367-6733 *
TREMBLAY G B ET AL: "4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related(ERR) nuclear receptors beta and gamma", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 142, no. 10, 2001, pages 4572 - 4575, XP002967678, ISSN: 0013-7227 *

Also Published As

Publication number Publication date
JP2005509628A (ja) 2005-04-14
AU2002342058A1 (en) 2003-04-28
WO2003034028A2 (fr) 2003-04-24
EP1436395A2 (fr) 2004-07-14
WO2003034028A3 (fr) 2004-02-19

Similar Documents

Publication Publication Date Title
EP1534273A4 (fr) Modulateurs de recepteurs de glucocorticoides et procede associe
IL159959A0 (en) Method and device for image display
EG25606A (en) Glucocorticoid receptor modulators
TWI340738B (en) Modulators of the glucocorticoid receptor
HRP20141228T1 (en) Compounds and methods for development of ret modulators
NO20020912L (no) Bicykliske androgen- og progesteronreseptorer- modulatorforbindelser og fremgangsmåter
IL165792A0 (en) N-bridged selective androgen receptor modulators and methods of use thereof
EP1521747A4 (fr) Modulateurs de kinase de type recepteur et procedes d'utilisation
GB0110748D0 (en) Image enhancement methods and apparatus therefor
IL158197A0 (en) Methods and apparatus for truncation compensation
EP1405219A4 (fr) Procede et dispositif d'integration d'applications d'entreprise
AU8689201A (en) Methods and devices for quantitative analysis of x-ray images
IL155005A0 (en) Compounds and methods for modulation of estrogen receptors
EP1420677A4 (fr) Dispositif de fermeture et procede d'installation associe
AU2002231979A1 (en) Modulators of p53-p300 interactions and screening methods therefor
AU2002323079A1 (en) Estrogen receptor alpha variants and methods of detection thereof
EP1436395A4 (fr) Methodes d'identification et d'utilisation de modulateurs du recepteur gamma dependant des oestrogenes
AU2002364612A8 (en) Methods and materials for modulating enac-beta
AU2003216354A8 (en) Modulators of paraptosis and related methods
AU2001249107A1 (en) Methods of assaying for g protein-coupled receptor ligands and modulators
AU9119201A (en) Screening systems and methods for identifying modulators of xenobiotic metabolism
SG108854A1 (en) Method and apparatus for distributing clocks
AU2001283463A1 (en) Methods of diagnosis of cancer and screening for cancer modulators
AU2002360354A1 (en) Methods of identifying and using modulators of fractalkine receptor
AU2001242357A8 (en) Method and device for software development

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040416

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20061030BHEP

Ipc: C07K 14/00 20060101ALI20061030BHEP

Ipc: C12N 5/00 20060101ALI20061030BHEP

Ipc: C12N 15/63 20060101ALI20061030BHEP

Ipc: C12N 15/12 20060101AFI20040422BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20061109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070209